Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: Eight years on

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Insulin-like growth factor (IGF)-I, and its main binding protein, IGFBP-3, are multi-functional regulatory peptides of cell growth and survival, attributes important for tumourigenesis. Following seminal work published in 1998, it has been hypothesised that circulating concentrations of these growth factors may be associated with cancer risk. Systematic reviews have reported that high normal range circulating levels of total IGF-I predict for pre- but not post-menopausal breast cancer. By contrast, associations with circulating IGFBP-3 have been inconsistent. A cumulative meta-analysis demonstrates that earlier reported positive associations between IGFBP-3 and pre-menopausal breast cancer risk now seem less clear as large-size cohorts are published. The reasons are complex and include differences in study design, lack of standardisation between assays, and variations in IGFBP-3 proteolytic activity - these are discussed in this commentary. © 2006 Society for Endocrinology.
    Original languageEnglish
    Pages (from-to)273-278
    Number of pages5
    JournalEndocrine-related cancer
    Volume13
    Issue number2
    DOIs
    Publication statusPublished - Jun 2006

    Keywords

    • blood: Breast Neoplasms
    • Female
    • Humans
    • blood: Insulin-Like Growth Factor Binding Protein 3
    • analysis: Insulin-Like Growth Factor I
    • Risk Factors

    Fingerprint

    Dive into the research topics of 'Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: Eight years on'. Together they form a unique fingerprint.

    Cite this